- 米国企業
- Ayala Pharmaceuticals, Inc.
Ayala Pharmaceuticals, Inc.ADXS
時価総額
$236.5万
PER
| 2013年 10月31日 | 2014年 10月31日 | 2015年 10月31日 | 2016年 10月31日 | 2017年 10月31日 | 2018年 10月31日 | 2019年 10月31日 | 2020年 10月31日 | 2021年 10月31日 | 2022年 10月31日 | |
| Revenue | 2 | 1,000,000 | - | 4 | 12 | 6 | 21 | 0 | 3 | 0 |
| Research and development expenses | 35 | 9 | 24 | 49 | 72 | 57 | 27 | 16 | 11 | 8 |
| General and administrative expenses | 36 | 12 | 24 | 32 | 39 | 19 | 12 | 11 | 11 | 9 |
| Intangible asset impairment | - | - | - | - | - | - | - | - | - | 3 |
| Total operating expenses | 71 | 21 | 49 | 80 | 111 | 76 | 39 | 27 | 22 | 20 |
| Loss from operations | -14,693,602 | -19,538,578 | -48,670,657 | -76,492,238 | -98,527,876 | -70 | -18 | -26 | -19 | -19 |
| Interest income | - | - | 114,219 | 331,529 | 669,759 | 1 | - | 0 | 0 | 0 |
| Net changes in fair value of derivative liabilities | - | - | - | 69,055 | 20,156 | 3 | 3 | - | 1 | 5 |
| Other expense | 188,833 | 36,305 | -35,079 | -201 | -123 | -0 | -0 | - | - | -0 |
| Net loss before income taxes | -20,712,016 | -18,882,194 | -48,640,467 | -76,091,855 | -97,838,084 | -66 | -17 | -26 | -18 | -14 |
| Income tax expense | -725,190 | -2,356,880 | -1,609,349 | -2,535,625 | -4,402,682 | 0 | 0 | 0 | 0 | 0 |
| Net loss | -19,986,826 | -16,525,314 | -47,031,118 | -73,556,230 | -93,435,402 | -67 | -17 | -26 | -18 | -14 |
| Accretion of discount and redemption feature of convertible preferred stock | - | - | - | - | - | - | - | - | - | 1 |
| Income available to common stockholders | -20,541,826 | -16,525,314 | - | - | - | - | - | - | - | -15 |
| Net loss per common share, basic and diluted | -4.1 | -0.97 | - | - | - | - | - | - | - | -8.46 |